×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
PDSB – pds biotechnology corporation (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
PDSB
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
5/26
06:44 am
pdsb
PDS Biotechnology Shares Rise After Releasing Early Drug Data [MarketWatch]
Medium
Report
PDS Biotechnology Shares Rise After Releasing Early Drug Data [MarketWatch]
5/25
05:00 pm
pdsb
PDS Biotech Announces Interim Data Demonstrates 12-Month Survival Rate of 87% with PDS0101 in Combination with KEYTRUDA® (pembrolizumab) for Head and Neck Cancer Patients
High
Report
PDS Biotech Announces Interim Data Demonstrates 12-Month Survival Rate of 87% with PDS0101 in Combination with KEYTRUDA® (pembrolizumab) for Head and Neck Cancer Patients
5/18
08:00 am
pdsb
PDS Biotech Completes Enrollment in Immune Checkpoint Inhibitor Naïve Arm of VERSATILE-002 Phase 2 Clinical Trial in Advanced HPV16 Positive Head and Neck Cancer
Low
Report
PDS Biotech Completes Enrollment in Immune Checkpoint Inhibitor Naïve Arm of VERSATILE-002 Phase 2 Clinical Trial in Advanced HPV16 Positive Head and Neck Cancer
5/15
12:46 pm
pdsb
PDS Biotechnology Corporation (PDSB) Q1 2023 Earnings Call Transcript [Seeking Alpha]
Medium
Report
PDS Biotechnology Corporation (PDSB) Q1 2023 Earnings Call Transcript [Seeking Alpha]
5/15
07:30 am
pdsb
PDS Biotech Provides Business Update and Reports First Quarter 2023 Financial Results
Medium
Report
PDS Biotech Provides Business Update and Reports First Quarter 2023 Financial Results
5/4
08:00 am
pdsb
PDS Biotechnology Announces Conference Call and Webcast for First Quarter 2023 Financial Results
Low
Report
PDS Biotechnology Announces Conference Call and Webcast for First Quarter 2023 Financial Results
4/27
08:00 am
pdsb
PDS Biotech to Present Updated Data at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting Highlighting Combination of PDS0101 and KEYTRUDA® (pembrolizumab) in Head and Neck Cancer Patients
Medium
Report
PDS Biotech to Present Updated Data at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting Highlighting Combination of PDS0101 and KEYTRUDA® (pembrolizumab) in Head and Neck Cancer Patients
4/26
02:01 pm
pdsb
PDS Biotechnology: Late-Stage Biotech With Enormous Potential [Seeking Alpha]
Low
Report
PDS Biotechnology: Late-Stage Biotech With Enormous Potential [Seeking Alpha]
Date
Time
Symbol
Company Name
Action
%Chg
5/15/2023
07:30 am
pdsb
pds biotechnology corporation
MISS
Report
6.8%
pds biotechnology corporation
11/14/2022
07:30 am
pdsb
pds biotechnology corporation
MISS
Report
3.1%
pds biotechnology corporation
8/8/2022
07:00 am
pdsb
pds biotechnology corporation
BEAT
Report
-7.2%
pds biotechnology corporation
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
6/2
04:19 pm
pdsb
Form ARS PDS Biotechnology Corp For: Dec 31
Low
Report
Form ARS PDS Biotechnology Corp For: Dec 31
6/2
04:18 pm
pdsb
Form DEFA14A PDS Biotechnology Corp
Low
Report
Form DEFA14A PDS Biotechnology Corp
6/2
04:16 pm
pdsb
Form DEF 14A PDS Biotechnology Corp For: Jul 14
Low
Report
Form DEF 14A PDS Biotechnology Corp For: Jul 14
6/1
05:20 pm
pdsb
Form 8-K PDS Biotechnology Corp For: Jun 01
Medium
Report
Form 8-K PDS Biotechnology Corp For: Jun 01
5/25
05:03 pm
pdsb
Form 8-K PDS Biotechnology Corp For: May 25
High
Report
Form 8-K PDS Biotechnology Corp For: May 25
5/25
05:01 pm
pdsb
Form 8-K PDS Biotechnology Corp For: May 25
High
Report
Form 8-K PDS Biotechnology Corp For: May 25
5/18
05:17 pm
pdsb
Form 8-K PDS Biotechnology Corp For: May 18
Low
Report
Form 8-K PDS Biotechnology Corp For: May 18
5/17
04:49 pm
pdsb
Form 8-K PDS Biotechnology Corp For: May 17
Medium
Report
Form 8-K PDS Biotechnology Corp For: May 17
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
5/14
Q1/2019 3/31/2019 EPS 1.470 ZacksConsensus N/A ActVsEst N/A - N/A
41.4%
10/3 PDS Biotechnology Corp. Announces Clinical Collaboration with Merck 31.3%
2/5 PDS Biotechnology to Present at the 2020 BIO CEO & Investor Conference 16.3%
7/30 Form 8-K PDS Biotechnology Corp For: Jul 29 11.8%
10/22 PDS Biotechnology Completes Manufacturing of Clinical Batches of PDS0101 10.7%
11/25 PDS Biotechnology to Present at the World Vaccine & Immunotherapy Congress West Coast 2019 7.5%
12/3 PDS Biotechnology to Present at the 12th Annual LD Micro Main Event 6.7%
3/2 Form SC 13D PDS Biotechnology Corp Filed by: NETSCIENTIFIC PLC 6.6%
9/19 PDS Biotechnology Reports Clinical Data for Its Novel Immunotherapy PDS0101 in Follow up to Phase 1 Human Trial 6.1%
12/23 PDS Biotechnology Corporation (NASDAQ: PDSB) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $10.00 price target on the stock. 5.4%
10/3 PDS Biotechnology Corp. Announces Clinical Collaboration with Merck 31.3%
2/5 PDS Biotechnology to Present at the 2020 BIO CEO & Investor Conference 16.3%
7/30 Form 8-K PDS Biotechnology Corp For: Jul 29 11.8%
10/22 PDS Biotechnology Completes Manufacturing of Clinical Batches of PDS0101 10.7%
11/25 PDS Biotechnology to Present at the World Vaccine & Immunotherapy Congress West Coast 2019 7.5%
12/3 PDS Biotechnology to Present at the 12th Annual LD Micro Main Event 6.7%
3/2 Form SC 13D PDS Biotechnology Corp Filed by: NETSCIENTIFIC PLC 6.6%
9/19 PDS Biotechnology Reports Clinical Data for Its Novel Immunotherapy PDS0101 in Follow up to Phase 1 Human Trial 6.1%
12/23 PDS Biotechnology Corporation (NASDAQ: PDSB) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $10.00 price target on the stock. 5.4%
TOP News Decliners
2/11
PDS Biotechnology Corporation Announces Pricing of Public Offering of Approximately $12 Million of Shares of Common Stock
-25.8%
9/24 Form 8-K PDS Biotechnology Corp For: Sep 24 -15.4%
12/17 Form S-1 PDS Biotechnology Corp -14.9%
3/9 PDS Biotechnology Corporation (NASDAQ: PDSB) is now covered by analysts at Noble Financial. They set an "outperform" rating and a $5.45 price target on the stock. -14.2%
12/13 Form 8-K PDS Biotechnology Corp For: Dec 11 -13.5%
2/11 Form FWP PDS Biotechnology Corp Filed by: PDS Biotechnology Corp -12.7%
11/14 Form S-8 PDS Biotechnology Corp -12.7%
4/16 PDS Biotechnology Initiates Novel Vaccine Development Programs For COVID-19 and Universal Influenza; Delay of PDS0101 VERSATILE-002 trial -9.8%
11/25 Form 8-K PDS Biotechnology Corp For: Nov 25 -8.8%
6/4 Form S-8 PDS Biotechnology Corp -8.4%
9/24 Form 8-K PDS Biotechnology Corp For: Sep 24 -15.4%
12/17 Form S-1 PDS Biotechnology Corp -14.9%
3/9 PDS Biotechnology Corporation (NASDAQ: PDSB) is now covered by analysts at Noble Financial. They set an "outperform" rating and a $5.45 price target on the stock. -14.2%
12/13 Form 8-K PDS Biotechnology Corp For: Dec 11 -13.5%
2/11 Form FWP PDS Biotechnology Corp Filed by: PDS Biotechnology Corp -12.7%
11/14 Form S-8 PDS Biotechnology Corp -12.7%
4/16 PDS Biotechnology Initiates Novel Vaccine Development Programs For COVID-19 and Universal Influenza; Delay of PDS0101 VERSATILE-002 trial -9.8%
11/25 Form 8-K PDS Biotechnology Corp For: Nov 25 -8.8%
6/4 Form S-8 PDS Biotechnology Corp -8.4%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: